Marice Alcantara - Concepedia

Author

Marice Alcantara

City of Hope ORCID

Also Known As

Marice Alcantara, Marice B Alcantara, Marice B. Alcantara

Publications

768

Citations

H-Index

Concepts

All Affiliations

City of Hope Beckman Research Institute Yale University Translational Genomics Research Institute The University of Texas MD Anderson Cancer Center

About

Marice Alcantara is an author at City of Hope specializing in cancer therapeutics, medicine, and antimicrobial stewardship.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	1	1	20
2	Medicine	1	1	20
3	Immunology	1	1	20
4	Pharmacology	1	1	20
5	Antibiotics	1	1	20

Marice Alcantara

Publications

704

Citations

H-Index

Page 1

	Year	Citations
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial Nazlı Dizman, Luís Meza, Paulo Gustavo Bergerot, Nature Medicine	2022	427
Myeloid cell–targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell–mediated immunity Dayson Moreira, Sagus Sampath, Haejung Won, Journal of Clinical Investigation	2020	79
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial Hedyeh Ebrahimi, Nazlı Dizman, Luís Meza, Nature Medicine	2024	64
Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma Alex Chehrazi‐Raffle, Luís Meza, Marice Alcantara, Journal for ImmunoTherapy of Cancer	2021	37
Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3 Jeremy Hall, Zhuoran Zhang, S. Bhattacharya, Molecular Therapy — Nucleic Acids	2024	29
Pigment epithelium-derived factor upregulates collagen I and downregulates matrix metalloproteinase 2 in osteosarcoma cells, and colocalises to collagen I and heat shock protein 47 in fetal and adult bone Marice Alcantara, Natalie Nemazannikova, Mina Elahy, Journal of Pharmacy and Pharmacology	2014	20
Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial. Hedyeh Ebrahimi, Luís Meza, Keehoon Lee, Journal of Clinical Oncology Randomized Clinical TrialImmunodeficienciesImmunologyPharmacotherapyAntimicrobial Chemotherapy	2023	20
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy Marice Alcantara, Wilson S. Tang, Dongfang Wang, Frontiers in Immunology	2024	16
Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy Zhuoran Zhang, Xingli Zhao, Dongfang Wang, Molecular Therapy	2020	12

Page 1